Abstract:Background & aims: 2'-Fucosyllactose (2'-FL), the primary constituent of human milk oligosaccharides, has been identified as a potential regulator of inflammation in inflammatory bowel disease. Despite this recognition, the specific mechanisms through which 2'-FL alleviates ulcerative colitis (UC) remain ambiguous. This study seeks to investigate the potential anti-inflammatory properties of 2'-FL concerning intestinal inflammation and uncover the associated mechanisms.Methods: C57BL/6J mice were orally administered a daily dose of 500 mg/kg 2'-FL for 11 consecutive days, followed by the induction of colitis using 3 % (wt/vol) dextran sulfate sodium (DSS) for the final 6 days. Subsequently, a comprehensive range of techniques, including an Acyl-biotin exchange assay, fluorescein-isothiocyanate-labeled dextran assay, histopathology, ELISA, quantitative real-time PCR, Western blot, immunofluorescence staining, immunohistochemistry staining, Alcian blue-periodic acid schiff staining, TdT-mediated dUTP nick end labeling, transmission electron microscopy, iTRAQ quanti-tative proteomics, bioinformatics analysis, and the generation of signal transducer and activator of transcription 3 (STAT3) knockout mice, were employed to explore the relevant molecular mechanisms.Results: Administration of 2'-FL significantly ameliorated DSS-induced colitis in mice and enhanced the integrity of the intestinal mucosal barrier. 2'-FL downregulated the phosphorylation of STAT3 and inhibited STAT3-related signaling pathways in colon tissues, which, in turn, reduced inflammatory re-sponses. Interestingly, knockdown of STAT3 attenuated the protective effects of 2'-FL, highlighting that 2'-FL-mediated inflammatory attenuation is dependent on STAT3 expression. Additionally, 2'-FL could influence STAT3 activation by modulating the palmitoylation and depalmitoylation of STAT3.Conclusions: 2'-FL promotes the recovery of the intestinal mucosal barrier and suppresses inflammation in ulcerative colitis by inhibiting the palmitoylation and phosphorylation of STAT3.(c) 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Exogenous L ‐fucose Protects the Intestinal Mucosal Barrier Depending on Upregulation of FUT2‐mediated Fucosylation of Intestinal Epithelial Cells

Gut microbiota-mediated lysophosphatidylcholine generation promotes colitis in intestinal epithelium-specific Fut2 deficiency

Fucose Ameliorate Intestinal Inflammation Through Modulating the Crosstalk Between Bile Acids and Gut Microbiota in a Chronic Colitis Murine Model.

Fucose ameliorates the proinflammatory property of Fusobacterium nucleatum in colitis via altering its metabolism

Promoting Effect of L-Fucose on the Regeneration of Intestinal Stem Cells through AHR/IL-22 Pathway of Intestinal Lamina Propria Monocytes

FUT2-dependent fucosylation of HYOU1 protects intestinal stem cells against inflammatory injury by regulating unfolded protein response

L-Fucose Ameliorates DSS-induced Acute Colitis Via Inhibiting Macrophage M1 Polarization and Inhibiting NLRP3 Inflammasome and NF-kB Activation.

Intestinal Epithelium-Specific Fut2 Deficiency Promotes Colorectal Cancer Through Down-Regulating Fucosylation of MCAM.

2′-Fucosyllactose Ameliorates Inflammatory Bowel Disease by Modulating Gut Microbiota and Promoting MUC2 Expression

In Vitro Faecal Fermentation Metabolites of 2′-Fucosyllactose Protect Against Intestinal Epithelial Injury: Infant Enterotype Effects

2'-Fucosyllactose Promotes Colonization of Akkermansia muciniphila and Prevents Colitis In Vitro and in Mice

Fucose Promotes Intestinal Stem Cell-Mediated Intestinal Epithelial Development Through Promoting Akkermansia-related Propanoate Metabolism.

Faecal Microbiota Transplantation Reduces Susceptibility to Epithelial Injury and Modulates Tryptophan Metabolism of the Microbial Community in a Piglet Model

Fucoxanthin alleviates lipopolysaccharide-induced intestinal barrier injury in mice

2'-Fucosyllactose Restores the Intestinal Mucosal Barrier in Ulcerative Colitis by Inhibiting STAT3 Palmitoylation and Phosphorylation

L-fucose ameliorates the carcinogenic properties of Fusobacterium nucleatum in colorectal cancer

Regulatory Effect of Fucoidan Hydrolysates on Lipopolysaccharide-Induced Inflammation and Intestinal Barrier Dysfunction in Caco-2 and RAW264.7 Cells Co-Cultures

Deficiency of Intestinal Α1‐2‐fucosylation Exacerbates Ethanol‐Induced Liver Disease in Mice

Fucoidan Alleviates Colitis and Metabolic Disorder by Protecting the Intestinal Barrier, Suppressing the MAPK/NF‐κB Pathways, and Regulating the Gut Microbiota

Bacterial and host fucosylation maintain IgA homeostasis to limit intestinal inflammation in mice

Human Milk Oligosaccharide 2′-Fucosyllactose Alleviates DSS-induced Ulcerative Colitis Via Improving Intestinal Barrier Function and Regulating Gut Microbiota